Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion ...

Sanofi's (SNY) plans to seperate its consumer care unit draws buyout bids with over €10B in funding committed from banks and ...

Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

Sanofi (SNY) has won bindings bids for its consumer health division from private equity firms CD&R and PAI Partners. Read ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...

Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.

After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases 24 abstracts for Dupixent, including 4 oral presentations, highlight impact of ...

The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...